Genetic and expression analyses of the STOP (MAP6) gene in schizophrenia

Schizophrenia Research
Hiromitsu ShimizuTakeo Yoshikawa

Abstract

Accumulating evidence suggests that the pathologic lesions of schizophrenia may in part be due to the altered cytoskeletal architecture of neurons. Microtubule-associated proteins (MAPs) that bind to cytoskeletal microtubules to stabilize their assembly are prominently expressed in neurons. Of the MAPs, MAP6 (STOP) has a particular relevance to schizophrenia pathology, since mice deficient in the gene display neuroleptic-responsive behavioral defects. Here we examined the genetic contribution of MAP6 to schizophrenia in a case (n = 570) -control (n = 570) study, using dense single nucleotide polymorphism (SNP) markers. We detected nominal allelic (p = 0.0291) and haplotypic (global p = 0.0343 for 2 SNP-window, global p = 0.0138 for 3 SNP-window) associations between the 3' genomic interval of the gene and schizophrenia. MAP6 transcripts are expressed as two isoforms. A postmortem brain expression study showed up-regulation of mRNA isoform 2 in the prefrontal cortex (Brodmann's area 46) of patients with schizophrenia. These data suggest that the contribution of MAP6 to the processes that lead to schizophrenia should be further investigated.

Associated Clinical Trials

References

Sep 1, 1984·Proceedings of the National Academy of Sciences of the United States of America·L I BinderL I Rebhun
Jan 1, 1995·Cytogenetics and Cell Genetics·S IkegawaY Nakamura
Jan 1, 1997·Journal of Psychopharmacology·F W DeakinJ S Hellewell
Mar 9, 2000·Schizophrenia Research·D CotterI P Everall
Jun 3, 2000·Genetics·J K PritchardP Donnelly
Jul 29, 2000·Schizophrenia Research·E F TorreyR H Yolken
May 25, 2002·Science·Stacey B GabrielDavid Altshuler
Jun 13, 2003·American Journal of Human Genetics·Cathryn M LewisTomas Helgason
Aug 14, 2003·Genetic Epidemiology·Frank Dudbridge
Oct 22, 2003·Biochemistry·Christophe BoscDidier Job
Aug 7, 2004·Bioinformatics·J C BarrettM J Daly
Sep 15, 2004·Biological Psychiatry·Masayuki IdeTakeo Yoshikawa
Nov 4, 2004·Biological Psychiatry·Kazuo YamadaTakeo Yoshikawa
Dec 8, 2004·Current Drug Targets. CNS and Neurological Disorders·G Benitez-KingI Meza
Oct 29, 2005·Nature·UNKNOWN International HapMap Consortium

❮ Previous
Next ❯

Citations

Jan 3, 2014·Clinical Epigenetics·Melkaye G MelkaShiva M Singh
Nov 16, 2007·PLoS Biology·Akiko WatanabeTakeo Yoshikawa
Mar 26, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Kosuke KajitaniGeorge S Robertson
Sep 25, 2012·Schizophrenia Bulletin·Julien VolleMarie-Françoise Suaud-Chagny
Jan 23, 2016·Frontiers in Molecular Neuroscience·Antonio Benítez-Burraco, Juan Uriagereka
Jul 6, 2010·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Efrat DresnerIllana Gozes
Feb 25, 2009·Molecular and Cellular Neurosciences·Marion RichardVéronique Pellier-Monnin
Dec 18, 2007·American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics·Chihiro KakiuchiTadafumi Kato
Oct 26, 2010·Journal of Neurochemistry·Vincent FournetMarie-Pascale Martres
Feb 12, 2014·Progress in Neuro-psychopharmacology & Biological Psychiatry·Alan S BrownAndrew J Dwork
Oct 19, 2016·Cytoskeleton·Francesca MarchisellaPatrik Hollos
Oct 20, 2006·Journal of Psychopharmacology·Sharon L EastwoodPaul J Harrison
Jun 15, 2007·Synapse·Mélina BégouMarie-Françoise Suaud-Chagny
Jan 18, 2008·Journal of Neurochemistry·Caroline Bouvrais-VeretMarie-Pascale Martres
Jul 9, 2013·The Journal of Biological Chemistry·Julien LefèvrePatrick A Curmi
Apr 16, 2019·The British Journal of Radiology·Sue Y YiJohn-Paul J Yu
Sep 30, 2010·Immunopharmacology and Immunotoxicology·Simona Lucia BavaroDarja Kanduc
Dec 11, 2020·Schizophrenia Research·Valentine BouetMichel Boulouard
May 25, 2021·Frontiers in Molecular Neuroscience·Camille CuveillierAnnie Andrieux

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here